Top 5 High Dividend Stocks To Watch Right Now

A recent article on Benzinga detailed how to use sniper tactics to buy stocks when the dividend yields are higher.

The method involved setting a dividend yield as the target, and then buying at that price. From that, the stock has a lower price and a higher dividend yield.

There are many blue chip stocks with high dividends and high betas such as BP PLC (NYSE: BP), the major oil firm, and Caterpillar (NYSE: CAT) -- the world's largest heavy equipment maker and a member of the Dow Jones Industrial Average.

Another one to consider is Cohen & Steers Inc (NYSE: CNS), an asset manager based in New York City.

Hot Internet Companies To Buy Right Now: Allied World Assurance Company Holdings AG (AWH)

Allied World Assurance Company Holdings, AG operates as a specialty insurance and reinsurance company in Bermuda, Hong Kong, Ireland, Singapore, Switzerland, the United Kingdom, and the United States. It offers casualty insurance products that provide coverage for specialty type risks, such as professional liability, environmental liability, product liability, inland marine liability, healthcare liability risks, and commercial general liability products, as well as professional liability products, including policies covering directors and officers, employment practices, and fiduciary liability insurance. The company also provides a mix of errors and omissions liability coverages for various service providers comprising law firms, technology companies, insurance companies, insurance agents and brokers, and municipalities; primary and excess liability, and other casualty coverages to the healthcare industry, including hospitals and hospital systems, managed care organization s, and medical facilities, such as home care providers, specialized surgery and rehabilitation centers, and outpatient clinics; and general casualty products for a range of industries consisting of construction, real estate, public entities, retailers, manufacturing, transportation, and finance and insurance services, as well as workers compensation insurance products. In addition, it offers property insurance products covering physical property and business interruption for commercial property risks; and general property products covering risks for retail chains, real estate, manufacturers, hotels and casinos, and municipalities. Further, the company provides the reinsurance of property, general casualty, professional liability, specialty lines, property catastrophe, accident and health, and marine and aviation coverages. Allied World Assurance Company Holdings, AG was founded in 2001 and is headquartered in Baar, Switzerland.

Advisors' Opinion:

• [By Rich Duprey]

  Specialty insurance provider�Allied World Assurance (NYSE: AWH  ) announced yesterday its second-quarter dividend of $0.50 per share, a 33% increase from the payout it made last quarter of $0.375 per share, as approved by shareholders at the annual meeting last month.

• [By , Zacks Investment Research]

  Here are five�stocks that made it through this week’s screen:

  AmTrust Financial (AFSI) Allied World Assurance (AWH) Chatham Lodging Trust (CLDT) Federated National Holding Co. (FNHC) Whitewave Foods (WWAV)

  Get the rest of the stocks on this list and start screening for these companies on your own.

Top 5 High Dividend Stocks To Watch Right Now: Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.

MM-398

MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.

The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.

MM-121

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.

MM-111

MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.

MM-302

MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.

MM-151

MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 biopharmaceuticals player that's just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.

  If you take a look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it's now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.

  Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.

  Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha

• [By Roberto Pedone]

   

  Another stock that insiders are jumping into here is Merrimack Pharmaceuticals (MACK), which is engaged in discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the U.S. Insiders are buying this stock into major strength, since shares have ripped higher by 38% so far in 2014.

   

   

  Merrimack Pharmaceuticals has a market cap of $765 million and an enterprise value of $713 million. This stock trades at a premium valuation, with a price-to-sales of 16.04. Its estimated growth rate for this year is 12.1, and for next year it's pegged at 17.2%. This is just barely a cash-rich company, since the total cash position on its balance sheet is $124.18 million and its total debt is $113.81 million.

   

  A director just bought 36,000 shares, or about $246,000 worth of stock, at $6.84 per share. Another director also just bought 32,390 shares, or about $221,000 worth of stock, at $6.84 per share.

   

  From a technical perspective, MACK is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock recently sold off from around $8 a share to right around its 50-day moving average of $6.69 a share. Following that move, shares of MACK have started to rebound and re-fill a previous gap-down-day zone that started near $8. That spike higher into the gap is starting to push shares of MACK within range of triggering a big breakout trade.

   

  If you're in the bull camp on MACK, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.69 and then once it breaks out above some near-term overhead resistance levels at $7.97 to its 52-week high of $8.25 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.24 million shares. If that brea

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�

Top 5 High Dividend Stocks To Watch Right Now: Rossi Residencial SA (RSID3)

Rossi Residencial SA is a Brazil-based company involved in the real estate sector. The Company is principally engaged in the development, construction and sale of residential and commercial real estate properties. In addition, it is involved in the subdivision of land and provision of civil engineering services. As of December 31, 2011, the Company had four subsidiaries, including Astir Assessoria Tecnica Imobiliaria e Participacoes Ltda, RCI Consultoria de Imoveis Ltda, Rossi Consultoria de Imoveis Ltda and Rossi Industria de Artefatos de Concreto Ltda, as well as a number of joint ventures, such as Argentea Empreendimentos SA, Damacena Empreendimentos SA, Minulo Empreendimentos SA and Nicandra Empreendimentos SA, among others. Advisors' Opinion:

• [By Ney Hayashi]

  MMX Mineracao & Metalicos SA rose to a one-week high after saying it is seeking partners to expand a mining project. Rossi Residencial SA (RSID3) led gains among homebuilders as traders reduced bets on higher borrowing costs. EDP-Energias do Brasil SA advanced after selling a stake in some of its power plants in Brazil to China Three Gorges Corp. Car-rental company Localiza Rent a Car SA climbed after Fitch Ratings increased its credit rating.

• [By Ney Hayashi]

  Rossi Residencial SA (RSID3) climbed 2.1 percent today to 2.98 reais, leading homebuilders higher, as traders pared bets for higher borrowing costs in Brazil following the inflation report. The BM&FBovespa Real Estate Index added 0.5 percent.

Top 5 High Dividend Stocks To Watch Right Now: FirstEnergy Corporation(FE)

Firstenergy Corp. operates as a diversified energy company. The company, through its subsidiaries and affiliates, involves in the generation, transmission, and distribution of electricity, as well as energy management and other energy-related services. It serves approximately 6 million customers within 67,000 square miles through 10 utility operating companies in Ohio, Pennsylvania, New Jersey, West Virginia and Maryland. The company was founded in 1996 and is headquartered in Akron, Ohio.

Advisors' Opinion:

• [By Justin Loiseau]

  AEP's not alone. FirstEnergy (NYSE: FE  ) announced earlier this month that it plans to retire two more coal-fired power plants that currently account for a whopping 10% (2,080 MW) of its total capacity.

• [By David Dittman]

  FirstEnergy Corp (NYSE: FE) is perhaps the riskiest play among the six stocks listed in the table. FirstEnergy is coming off a 34.5 percent dividend cut announced in January 2014 following a ��horough��study of the company�� businesses. The board concluded that a dividend rate ��ligned��with revenue and earnings generated by regulated operations ��ill provide the best path forward for FirstEnergy.��/p>

• [By Lu Wang]

  Exelon tumbled 9.6 percent to $31.34. The largest U.S. operator of nuclear reactors was cut to hold from buy at Deutsche Bank AG. FirstEnergy (FE) Corp. slid 8.5 percent to $39.01. The utility company was cut to neutral from outperform at Credit Suisse Group AG.

• [By Johanna Bennett]

  FirstEnergy (FE) fell 5.7%. The power company last week narrowed its full-year outlook.

  Denbury Resources (DNR) shares dropped 5.9% after oil-and-natural-gas explorer on Sunday announced that it will initiate quarterly dividend and raised its share repurchase plan to $250 million from the $109 million remaining in its program.